Good morning and thank you for standing by. Welcome to the AbbVie Second Quarter 2015 Earnings Conference Call. All participants will be able to listen-only until the question-and-answer portion of this call. [Operator Instructions] I would now like to introduce Mr. Larry Peepo, Vice President of Investor Relations.

Good morning and thanks for joining us. Also on the call with me today are Rick Gonzalez, Chairman of the Board and Chief Executive Officer; Laura Schumacher, Executive Vice President Business Development, External Affairs and General Counsel; Michael Severino, Executive Vice President of Research & Development and Chief Scientific Officer; and Bill Chase, Executive Vice President of Finance and Chief Financial Officer. Before we get started, I’ll remind you that some statements we make today may be considered forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Additional information about the factors that may affect AbbVie’s operations is included in our 2014 Annual report on Form 10-K and in our other SEC filings. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments except as required by law. On today’s conference call as in the past, non-GAAP financial measures will be used to help investors understand AbbVie’s ongoing business performance. These non-GAAP financial measures are reconciled with comparable GAAP financial measures in our earnings release and regulatory filings from today, which can be found on our website. Following our prepared remarks, we’ll take your questions. So with that, I’ll now turn the call over to Rick.

Thank you, Larry. Good morning everyone and thank you for joining us for our second quarter 2015 earnings conference call. We delivered another strong performance with second quarter results ahead of our expectations including adjusted earnings per share of $1.08 representing growth of more than 31% versus the second quarter of 2014. Our results included strong operational sales growth of nearly 20% driven by a number of products across the portfolio including strong performance from our newly acquired oncology therapy, IMBRUVICA, continued global uptake of VIEKIRA and continued strong growth from HUMIRA as well as other products in our portfolio including Creon, Synthroid, and Duodopa. We are particularly pleased with the high quality of our results in the quarter. We saw significant margin expansion, continued R&D investment and SG&A leverage and we delivered these results despite a significant foreign exchange headwind. We are also pleased with our outperformance and progress year-to-date. We've driven strong commercial, operational and R&D execution resulting in industry-leading top and bottom line performance. During the quarter, we advanced several important strategic priorities, continued to enhance operational efficiency and achieved a number of regulatory and clinical objectives. Importantly, we completed the acquisition of Pharmacyclics augmenting AbbVie's already strong position and growth prospects. I'll discuss our progress with Pharmacyclics in more detail in just a moment. We are also driving strong performance from our current portfolio, including HUMIRA which is off to a very good start in the first half of the year with robust underlying global demand and exceptional performance in the U.S. We made significant progress with our mid- and our late-stage R&D programs. During today's call our Chief Scientific Officer, Mike Severino will provide an update on our pipeline. And we've also continued to improve efficiency across our operations delivering roughly 800 basis points in…

Thank you, Rick. It's an exciting time to be leading research and development at AbbVie. We've got a broad and robust pipeline that includes more than 40 active clinical development programs, including 10 programs in late-stage development or under regulatory review. Our core areas of focus include immunology where we're leveraging our deep expertise to develop next-generation biologics from small molecules that elevate the standard-of-care. Oncology, including assets to address both hematologic malignancies and solid tumors, neuroscience with a particular focus on developing disease modifying therapies for Alzheimer's and other neurotic, degenerative conditions, and virology with an emphasis on continuing to evolve the ACB treatment landscape. We are also placing focused investment in our late-stage programs in women's health with elagolix and renal disease with Atrasentan. Today I'll cover each of these areas and highlight some of our most promising programs. In immunology, we've established clear leadership positions across therapeutic categories including rheumatology, dermatology and gastroenterology and we're leveraging our expertise to build upon these strong positions. Our strategy is centered upon identifying treatments that offer differentiated profiles relative to currently available therapies with the goal of continuing to raise the standard-of-care. We have several promising assets in development including two oral selective JAK 1 inhibitors, several biologics and a bi-specific biologic currently in mid-stage trials. Most advanced are our two selective JAK 1 inhibitors on the cusp of completing mid-stage development in RA. As Rick mentioned, earlier this year our partner Galapagos announced positive topline interim data from two Phase 2b studies in RA. Over the next few months we will evaluate data from our internal program ABT-494 and make decisions about next steps. We also believe our DVD-Ig antibody platform holds tremendous promise in the treatment of immune mediated conditions. ABT-122 is our combination anti-TNF anti-IL-17 two validated…

Thank you, Mike. This morning I'll review our second quarter performance and provide an update on our outlook for 2015. As Rick said, we are very pleased with the strong quarter we delivered. Operational growth on the top-line was a very strong 19.4% excluding an 8.3% negative impact from foreign exchange. Reported sales were up more than 11%. HUMIRA delivered global sales of more than $3.5 billion, up 16.4% on an operational basis. We continue to see strong momentum for HUMIRA as the market leader around the world. On a reported basis currency had a negative 8.8% impact on global HUMIRA sales and reduced international HUMIRA sales by nearly 18%. U.S. HUMIRA sales increased nearly 29% driven by prescription volume and favorable pricing impacts. We've seen acceleration in market growth this year in the U.S. with HUMIRA driving double-digit growth in the gastro, rhum and derm segments. Wholesale inventory remained constant at less than half a notch. Internationally HUMIRA sales have grown nearly 9% on an operational basis in the first half of the year consistent with our planning capitalizations [ph]. As we noted last quarter, the first quarter international growth rate of nearly 15% was favorably impacted by the timing of shipments in select markets. Consequently international sales growth in the second quarter was negatively impacted by the shipment timing. Market growth internationally remained strong with most major markets experiencing double-digit growth and HUMIRA's international market share has remained stable despite new competitors and the launch of biosimilar infliximab. HUMIRA's momentum has not been adversely impacted by the biosimilar. For the full year 2015 we continue to expect global HUMIRA sales growth in the mid-teens on an operational basis. This reflects a forecast for the U.S. growth approaching 30% and 9% to 10% operational growth internationally. Global Viekira sales…

Thanks, Bill. We’ll now open the call up for questions. Operator, we’ll take our first question please.

Okay, sir. Thank you. [Operator Instructions] Our first question comes from Ms. Jami Rubin from Goldman Sachs. Your line is open.

Thank you very much. Hope you guys can hear me okay. With respect to HUMIRA international sales you've pointed to shipment timing, tough comparisons and FX as reasons for the underperformance, but wouldn’t REMICADE biosimilars be the real culprit here? What evidence specifically can you share with us that suggests that this quarter performance was more of a one-timer verses a new trend? I mean may be you can share what you're seeing in terms of market share changes et cetera? And then a question for your Rick, on potential for U.S. biosimilars, as you know Amgen filed an IPR on the two long data pats, may be you can talk to those patents that are being challenged and put that into the context of your broader patent defense strategy. Thanks very much.

Thanks, all right Jami. Jami, this is Rick, good morning. I'll take the first question and let Laura Schumacher answer the second question for you. So it’s a good question and I’m going to answer your question, I’d say very directly and very clearly because I want to make sure that there is no misunderstanding or confusion around this issue. But the bottom line when we’ve done is I would tell you that we have seen no impact from Remicade biosimilar on HUMIRA in the international market, but I’ll give you some color to be able to support that. so I'm going to go back to the first quarter, when we announced first quarter results, if you look at Bill’s formal remarks, in his remarks we identified the fact that they benefited from shipment timing and that is exactly what we’re seeing here and I would tell you that the impact we’re seeing here is consistent with what we expected in that. Secondly, I’d tell you that when we put out the original guidance on HUMIRA, both at the beginning of the year and then when we raised guidance, within that guidance range we had assumed international performance growth of HUMIRA at 9% to 10%. If you look at the performance in the first quarter, we delivered 14.9% growth in the first quarter, second quarter was 3.6%, the average for the two quarters or the first half of the year is 8.8%. We are confirming now explicitly that the second half is forecasted internationally to be 9% to 10% which is exactly what it was in the original guidance. We are also confirming the original guidance. So obviously we feel that we were sitting here with our toes hanging over the edge of the cliff that would be an awfully…

The IPR?

Go ahead on the IPR.

With respect to your question about Amgen’s IPR, as we’ve said before, we have a broad portfolio of IP covering manufacturing, process, formulation and methods that we use. Amgen’s IPR does not impact our patent strategy. We don’t know why Amgen selected the two formulation patents that it did to challenge, potentially challenge an IPR, but it does give some perspective on the breadth of our IP including over 40 additional patents that are not the subject of the IPR.

Thanks Jami. Operator we will take our next question please.

Okay sir. Our next question comes from Mr. Jeff Holford of Jefferies. Sir your line is open.

Hi, there does still seem to be a lot of noise on the line it is not coming from me. First question is on new HUMIRA, the one you just had approved in Europe. Can you just give us a bit more color around some numerical data, whatever you have on the clinical differentiators you seem to have on pain and injection volume, just give us a bit more review whether the label that you are getting is going to help you potentially do hard switches in some of the markets you were thinking about? And how this product could help you in the future potentially as a biosimilar defense mechanism, because that’s not entirely clear from this? And then just on Viekira contracts in the U.S., could you just give us any updates on how these are actually playing out versus how you thought they were going to, just some of the metrics that you are looking at? And then, just last question around Viekira, does your run rate for the last quarter of the year, the $3 billion run rate that you are looking at, does that assume a full quarter Japan, how important is that in your minds at achieving that run rate? Thanks very much.

Okay, very good. So Jeff, this is Rick. I’ll answer most of the first question. Let me see if Mike may be able to add a little bit of specificy. So there were two benefits that the new formation was designed to do. We know that there are patients who ultimately stop therapy with the current product because of the pain that they feel upon injection. So we know that’s an important driver of adherence of the product and so we designed this product as a differentiation. The clinical data Mike, I don’t recall the specific numbers, do you recall the actually percent?

This is Mike. So there are data in the studies that were submitted to regulatory agencies. We’re still waiting on a final labeling in the U.S. and Europe. So I think it’s probably a bit premature, numbers that might in labeling, but we assessed this in the course of the clinical development program.

But what I would say is, it’s a significant reduction in pain, a very significant reduction in pain. The second part is that this will also allow us to ultimately reduce the volume of injection, volume and therefore potentially over time reduce the number of injections particularly on the loading dose. So as we said before this is an incremental improvement to the product. We think it’s a meaningful improvement. We’ve obviously studied the different kinds of things that we could do HUMIRA. We have other things that we’re continuing to work on. But we think these are a meaningful opportunity to be able to launch the product. We haven’t formally decided exactly how the product will launch or at least formally announced how the product will launch. So I’m not going to talk through any details around whether or not it will a full conversion or ultimately a phased-in kind of an approach based on certain countries. And so that’s essentially how we see the product and we do think it will differentiated in a significant enough way. It will have both a material impact on HUMIRA itself, HUMIRA’s performance itself, as well as a differentiator versus competitors. So on Viekira pack as far as contracting is concerned I think the contracting hasn’t changed a lot in the U.S. from the last time we talked on the call. As we indicated we had a number of exclusive contracts that were coming online. They are now up and running. We are ramping within those particular contracts. I’d say we are ramping within the expectations that we expected. If you look at our single largest customer in the U.S., that’s an exclusive, we’ve now reached peak share there and so ultimately we’ve reached the level of share that we had anticipated,…

Thanks. That is very helpful color and congratulations on a great IMBRUVICA number.

Thanks Jeff. Next question operator.

Our next question comes from Mr. Mark Goodman of UBS. Sir your line is open.

Yes, good morning. First of all, you have a guidance range that is pretty wide, I was just wondering why you didn’t tighten it this quarter? Second you talked about immuno-oncology you would have multiple assets in the clinic by next year, can you talk about are these going to be similar types of assets to the PD-1 and PD-L1 things like that are they kind of the next wave of products?

Okay. This is Rick. I will cover the first one. We haven’t narrowed the guidance range yet, we probably will here as we get closer to third quarter narrow the guidance range. And I'd say the primary reason for that is foreign exchange has certainly been more challenging than we anticipated and we want to see how that plays out. We told investors that we were going to cover foreign exchange. That we weren’t going to do – we weren’t going to pass that on and so we just want to see another quarter’s worth of performance here and what foreign exchange does over that period of time to feel more comfortable that when we narrow the range or within a range that we are comfortable with. It is just that simple. And them Mike why don’t you talk about immuno-oncology?

Certainly, with respect to immuno-oncology, we’re really referring to the next wave of programs. These would be things beyond PD-1 and PD-L1 or perhaps they might combine well with those mechanisms, but we’re looking at driving for treatment results that can't be achieved today. So we would be referring to novel mechanisms.

Thanks Mark. Operator, we will take our next question please.

Our next question comes from Mr. Alex Arfaei from BMO Capital Markets. Sir, your line is open.

Good morning folks and thank you for taking my questions.

Good morning.

Regarding HUMIRA, you mentioned you are seeing accelerated market growth in the U.S. very impressive U.S. performance by the way. Are you seeing increased penetration of biologics in these markets or is it overall volume growth or both? And can you provide more color on some of the efficiencies we are seeing, some of the operating efficiencies we’re seeing? Where are you cutting and why? Thank you.

So Alex on HUMIRA, if you look at the U.S., it’s really been a remarkable story. If you look at market growth last year, it was in the 6% range. That has now moved to about a 13%. We’ve held that pretty steady across the quarter. So what that’s a sign of is that the SG&A that we put behind the brand continues to work and it continues to give a positive return. And the way that that growth is delivered is in fact by penetration as well as improved patient compliance and a number of other things. But there is definitely a penetration element that is the big growth driver in this market. And as you know all of the autoimmuno segments are relatively under penetrated versus what you would expect given the power of a biologic. So that is a big part of the story. In terms of efficiencies, look, we’ve been focused on efficiencies from the very beginning now they shake on the number of different places. In manufacturing, they are the traditional efficiencies you would expect, whether it be purchasing, better utilization of plants or in some cases even take offline non-productive capacity, we've done all of those sorts of things. Across the P&L though, leverage itself presents a different type of efficiency, right. We’re obviously no longer in a situation where we need to grow expense in at the same rate of the top line. In fact, if you look at our expense growth particularly on SG&A it is far, far, far, below what the top-line is growing and that’s pretty much the new model for this business now that we’ve made the investments we needed to make back in '13 and '14 and we’re on track to start delivering growth through the introduction of new products in '15 and beyond. So there are really two different types of efficiencies in the numbers.

Thank you.

Thanks, Alex. Next question please, operator.

Our next question comes from Mr. Mark Schoenebaum from Evercore ISI. Sir, your line is open.

Okay. Hey, guys, thanks a lot for the transparency, always the most detailed prepared remarks of any company, any big company, so thanks for that. I just want to go back to the central point that others have asked about. Because the stock is off right now and the consistent feedback I’m getting is that people are just very concerned about the rest of the world's HUMIRA numbers. So my question is really simple; one, what was the sequential volume growth for rest of the world HUMIRA? Two, what was the average change in price quarter-on-quarter in the 2Q, please? And then my second question if I may is, you guys I think as mentioned that you might contemplate in the Analyst Meeting or you might provide some long-term financial targets or vision and go over the pipeline, and then you would contemplate this once the PCYC deal is closed. So I’d just like to know what your current thinking is on that? Thank you and congratulations on a great stock move this quarter.

Thanks, Mark. So Mark on HUMIRA, the volume growth quarter-over-quarter was slightly above 10%, overall price was 6% on a global basis.

Do you have just rest of the world?

Rest of the world had negative price of 4.1 and volume was up over 7%.

The volume was up over 7%, rest of the world. Okay.

Yes.

Got it. People are very confused out there. Thank you.

Thank you.

And then Mark, this is Rick. On the Analyst Meeting, yes it is something we are still considering, I think as you indicated maybe in one of your remarks, I think timing wise if we decide to do it, it probably will be at the beginning of the year, maybe time with a major meeting where it would be convenient for investors to be able to participate. We haven’t made a final decision yet, but we will communicate something around that at some point here, probably third quarter.

And just to confirm the HUMIRA numbers, those were sequential correct?

Quarter-over-quarter 2015 versus '14.

Do you have the sequential numbers 1Q this year versus 2Q and then I’ll stop.

I don’t have them handy, because we don’t typically look it at that way. I would say price will be relatively flat quarter-to-quarter, price would be probably down about may be 2% quarter-over-quarter. But I don’t have a firm volume number for you. Would you followup with me on that?

Was it positive?

Yes.

It was positive. Okay. Thank you.

Was the price positive, he’s asking...

No price was negative.

Okay.

The volume was positive.

Thank you.

Thanks Mark. Next question please operator.

Our next question comes from Mr. Chris Schott from JPMorgan. Sir, your line is open.

Great. Thanks very much for the questions and just couple of quick ones here. First can you just quantify the impact to gross margins from FX in the quarter and in your annual guidance? I’m just trying to get a best sense of what type of underlying growth we are seeing on that gross margin line as we're going through the year here? The second question was on the IL-17 just would be interested in your perspective on what those products are going to kind of mean for the psoriasis market and as you think about HUMIRA over time? And a final one, just so I just come back to clarify some of the earlier comments on the new HUMIRA formulation and launch dynamics, just want to make sure I understood the comments. Should we think about when this product launches it is going to basically fully replace the prior version of HUMIRA in whatever countries it goes out in or is this going to be a conversion type process, we have to go to physicians, get them to select the new version for more of a gradual process? Just wanted to make sure I understood your earlier comments. Thanks very much.

So Chris, on gross margins I'm just going to just give you some numbers. So our gross margin was up about 570 basis points. Pharmacyclics diluted that by about 50 basis points. So if you exclude Pharmacyclics we are up 620 basis points, just over half of that was exchanged. And then for the year very similar story, different numbers but similar story, gross margin we are forecasting up around 300 basis points. Pharmacyclics will have about 90 basis points to a full point impact. So net-net excluding Pharmacyclics, you would expect to see about a 400 basis point improvement of which again just slightly over half is exchange.

Okay. So this is Mike. I’ll take the second component of your question. With respect to the IL-17s, I think clearly the IL-17s in plaque psoriasis demonstrate very strong efficacy. There are areas where their profile is not quite as compelling in psoriatic arthritis for example. The initial uptake of the 17s has been relatively slow. We would expect the dermatologist would take some time to become comfortable with the new mechanism before they would adopt it. So we feel comfortable about the trajectory of HUMIRA in the psoriasis space for quite some time.

Okay. And on the new formulation, I mean we really can’t talk specifically about what the strategy is because it’s somewhat condition on the regulatory approval and we don’t have regulatory approvals yet all around the world. But there probably will be situations where it will be a replacement product, meaning it will replace not over a very short period of time, but over a relatively short period of time as inventory runs out of the old product, the new product will replace the old product and we will only maintain the new product in the marketplace. I would say that will probably be the predominant model that is out there, but it might not be the exclusive model that is out there depending upon the regulatory approvals.

Thanks very much.

Thanks Chris. Next question please.

Our next question comes from Mr. Robyn Karnauskas of Deutsche Bank. Sir, your line is open.

Hello, it’s Mr. Robyn Karnauskas, thanks for taking my question.

Glad to meet you.

All right, so two quick questions, one you didn’t mentioned anything about celiac disease, I am wondering if you could comment on did the program fail or are you still interested in that program? Second question on HUMIRA II, the new HUMIRA, do you think will be able to track that in any way will it be given a different name? Just wondering like how the Street will be able to monitor that as it has an uptick? And then the last question big picture for your RA franchise given that looks like you don’t have to go through the patent dance and Amgen’s filing an IPR which could speed up sort of the clarity around when they are actually going to launch. How do you view the time lines for some of your emerging RA drugs and whether it is important to get them on the market sooner or whether or not you'll still be okay if Amgen’s biosimilar hits ahead of their launch? Thanks.

So, this is Mike. With respect to celiac disease, we're still evaluating the opportunity and we’ve not reached a decision point yet.

Okay and Robyn this is Rick. I will cover the HUMIRA formulation. Again it is consistent with what I described to you before. It will depend upon the regulatory approval. So we don’t know the answer to that yet. It could be that it has the exact same name as the current product and therefore you wouldn’t necessarily have any direct visibility to it. It could be HUMIRA plus some designation after HUMIRA and therefore we would be able to track it, or you would be able to track it in some separate fashion. So we’re going to see how that plays out before I can give you an accurate answer. And then, I'd just say on the big picture piece, I'd say the IPR doesn’t necessarily change anything that we thought about before from a timing standpoint. As we've said and as Laura mentioned a momentum ago, we have a broad group of, or portfolio of IP. We have some very important patents in this area and we intend to enforce those patents and this IPR process won’t affect those timelines as we’ve assumed it.

Okay, great. Thank you.

Thanks Robyn. Operator, we have time for one more question please.

Okay sir. Our last question comes from Mr. Steve Scala from Cowen. Sir your line is open.

Thank you and thanks for the R&D overview. AbbVie really does have an impressive pipeline. On the new HUMIRA formulation what portion of the current patients on HUMIRA have issues with pain and or volume? What additional IP protection does it offer? And then third, it sounds like there is a bit of hedging on the prior of Viekira guidance of annualizing as $3 billion exiting 2015 am I wrong? Thank you.

Thanks Steve. This is Rick. I guess I’ll do the last one first. I was trying to describe to you the elements that will drive our overall performance in Viekira. If I sounded like I was hedging, I apologize for that. It is our goal to still hit the number that we described to you. So I was trying to describe to you the elements associated with it. As far as the details around percentage of patients, I mean I don’t recall it offhand. I’d say there is a fairly substantial percentage of patients that when they first go on the drug do experience or express concern about pain upon injection. The vast majority of those patients obviously work through it and stay on the drug, but it’s not an insignificant percentage of patients that we see that, that experience at the beginning of their use of the product. And as far as volume, it’s more of a practical thing. At the end of the day if you inject less volume obviously that helps with the pain as well assuming it is not more viscous, so it has some other reason why would have pain. But if you - as you get less volume in the indications where you have loading doses, there would be a substantial benefit there, where you can go from multiple loading doses to one loading dose an example in certain conditions and I think that would be a significant benefit for patients.

And the IP?

I mean essentially it has IP associated with it, I'd say this is really a strategy to differentiate the product. Obviously we have IP around this particular formulation. I think that IP will protect this particular formulation. As we've described I think a couple of times before, we don’t view this as an absolute block. When you think about our biosimilar strategy, it’s a number of things that have all been put together, a very large portfolio of IP, some of that IP is very broad and very challenging I think for someone to work around. New formulations, it helps differentiate the product. Our commercial strategy, when and if biosimilar is launched and then our pipeline of new assets to be able to move into this market and I'd say although we tend not to probably be able to get there in any meaningful way, I think one of the exciting things that we see internally is if you look at the data that we’ve seen around the JAK 1 hypothesis that we have its is playing out and its playing out in a very positive way. And I think it’s a profile of a drug that we believe could have a meaningful impact in the marketplace and I think that would be an important product for us to advance and get into the marketplace and then also ABT-122, I think as we talk about an IL-17 combined with a TNF as we see that data, I think that product could have a very meaningful place in the market as well. And so I think we’re gaining a lot of encouragement about de-risking that mid-stage pipeline to ensure that we have some products that will follow on with HUMIRA.

Thank you.

Thanks Steve. And that concludes today’s conference call. If you would like to listen to a replay of the call please visit our website at abbvieinvestor.com. Thanks again to everyone for joining us.

That concludes today's conference. Thank you for participating. You may now disconnect.